Information

Related Research Units

Emergency Medicine Research
Computational Health Informatics Program Research

Research Background

Dr. Florence Bourgeois is an Associate Professor of Pediatrics at Harvard Medical School and a faculty member in the Computational Health Informatics Program at Boston Children’s Hospital. At Harvard Medical School, she is the Director of the Harvard-MIT Center for Regulatory Science where she leads interdisciplinary projects focused on pharmaceutical development pipelines, prescription drug utilization, FDA regulatory policies and incentive programs, and postmarketing safety surveillance of regulated products. She directs a Fellowship Program that trains scientists from diverse backgrounds in regulatory science.

At Boston Children’s Hospital, Dr. Bourgeois is the Director of the Pediatric Therapeutics and Regulatory Science Initiative, which focuses on pediatric-specific drug policy and regulation, and methods to advance evidence-based use of therapeutics in children. She has served as an Expert Visitor at the European Medicines Agency, evaluating the implementation of the EU’s Pediatric Regulation and its impact on increasing pediatric drug research and product labeling.

As faculty member in the Computational Health Informatics Program, Dr. Bourgeois is the Scientific Director of the Boston Children’s Hospital PrecisionLink Biobank. In this role, she collaborates on developing novel approaches and informatics-based tools to integrate clinical data with biospecimen metadata and develop scalable infrastructures to expand capacity for biomedical research in pediatric patient populations, especially those with rare diseases. Her clinical training is in pediatrics and pediatric emergency medicine, and her research has been funded by the NIH, AHRQ, FDA, and various foundations.

Dr. Bourgeois is a graduate of Yale University and Washington University School of Medicine in St. Louis. She completed her residency training in pediatrics and fellowship training in pediatric emergency medicine, both at Boston Children’s Hospital. She was a NRSA research fellow and obtained a Master in Public Health in clinical effectiveness at the Harvard T.H. Chan School of Public Health.

Publications

  1. Pediatric Exclusivity Revenues for Cancer Drugs. JAMA Pediatr. 2025 Jan 01; 179(1):91-93. View Abstract
  2. The potential of Generative Pre-trained Transformer 4 (GPT-4) to analyse medical notes in three different languages: a retrospective model-evaluation study. Lancet Digit Health. 2025 Jan; 7(1):e35-e43. View Abstract
  3. Publisher Correction: Conflict of interest disclosure in biomedical research: a review of current practices, biases, and the role of public registries in improving transparency. Res Integr Peer Rev. 2024 Dec 20; 9(1):13. View Abstract
  4. US FDA Approval of Pediatric Artificial Intelligence and Machine Learning-Enabled Medical Devices. JAMA Pediatr. 2024 Dec 16. View Abstract
  5. Mapping the Clinical Development Trajectory of Cell and Gene Therapy Products. Clin Pharmacol Ther. 2024 Dec 10. View Abstract
  6. FDA Approval of Orphan Drug Indications for Pediatric Patients, 2011-2023. JAMA Pediatr. 2024 Dec 09. View Abstract
  7. Naloxone Access Laws and Opioid-Related Overdose Deaths in Youths. JAMA Pediatr. 2024 Dec 01; 178(12):1368-1370. View Abstract
  8. The Association of the Child Opportunity Index with Emergency Department Presentations for Pediatric Poisonings: A Case-Control Study. J Pediatr. 2024 Nov 15; 277:114410. View Abstract
  9. The challenges of regulatory pluralism. Health Policy. 2024 Nov; 149:105164. View Abstract
  10. Enrollment of underserved racial and ethnic populations in pediatric asthma clinical trials. J Allergy Clin Immunol Glob. 2024 Nov; 3(4):100315. View Abstract
  11. Panel stacking is a threat to consensus statement validity. J Clin Epidemiol. 2024 Sep; 173:111428. View Abstract
  12. Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity. Stat Methods Med Res. 2024 Jul; 33(7):1152-1162. View Abstract
  13. National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector Cells. Transplant Cell Ther. 2024 Jun; 30(6):626.e1-626.e11. View Abstract
  14. Mental Health-Related Outpatient Visits Among Adolescents and Young Adults, 2006-2019. JAMA Netw Open. 2024 03 04; 7(3):e241468. View Abstract
  15. Enrollment of Pediatric Patients in COVID-19 Interventional Trials. JAMA Health Forum. 2023 Nov 03; 4(11):e233939. View Abstract
  16. National Patterns of Outpatient Follow-Up Visits After Emergency Care for Acute Bronchiolitis. JAMA Netw Open. 2023 10 02; 6(10):e2340082. View Abstract
  17. Endovascular Aneurysm Repair Devices as a Use Case for Postmarketing Surveillance of Medical Devices. JAMA Intern Med. 2023 10 01; 183(10):1090-1097. View Abstract
  18. A comparison of machine learning methods to find clinical trials for inclusion in new systematic reviews from their PROSPERO registrations prior to searching and screening. Res Synth Methods. 2024 Jan; 15(1):73-85. View Abstract
  19. Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium. EClinicalMedicine. 2023 Oct; 64:102212. View Abstract
  20. Resource utilization among children presenting with cannabis poisonings in the emergency department. Am J Emerg Med. 2023 Nov; 73:171-175. View Abstract
  21. Characteristics and Results of Pediatric Medical Device Studies: 2017-2022. Pediatrics. 2023 09 01; 152(3). View Abstract
  22. Clinical development of new drugs for adults and children with cancer, 2010-2020. J Natl Cancer Inst. 2023 08 08; 115(8):917-925. View Abstract
  23. Reporting and Representation of Participant Race and Ethnicity in National Institutes of Health-Funded Pediatric Clinical Trials. JAMA Netw Open. 2023 08 01; 6(8):e2331316. View Abstract
  24. Data Sharing for Pediatric Clinical Trials Funded by the US National Institutes of Health. JAMA Netw Open. 2023 07 03; 6(7):e2325342. View Abstract
  25. Clinical trials for paediatric cancers under new legislation in the USA. Lancet Child Adolesc Health. 2023 07; 7(7):e13. View Abstract
  26. Advancing Equity in Medical Device Development for Children. JAMA Pediatr. 2023 06 01; 177(6):561-562. View Abstract
  27. Association of prescription drug monitoring programs with benzodiazepine prescription dispensation and overdose in adolescents and young adults. Clin Toxicol (Phila). 2023 04; 61(4):234-240. View Abstract
  28. Dissemination of the Results of Pediatric Clinical Trials Funded by the US National Institutes of Health. JAMA. 2023 02 21; 329(7):590-592. View Abstract
  29. The state and future of pediatric research-an introductory overview : The state and future of pediatric research series. Pediatr Res. 2023 Jan 24. View Abstract
  30. Association of Prescription Drug Monitoring Programs With Opioid Prescribing and Overdose in Adolescents and Young Adults. Ann Emerg Med. 2023 04; 81(4):429-437. View Abstract
  31. High-risk Therapeutic Devices Approved by the US Food and Drug Administration for Use in Children and Adolescents From 2016 to 2021. JAMA Pediatr. 2023 01 01; 177(1):98-100. View Abstract
  32. Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020. Pediatr Blood Cancer. 2023 05; 70(5):e30106. View Abstract
  33. Hospitalizations Associated With Mental Health Conditions Among Adolescents in the US and France During the COVID-19 Pandemic. JAMA Netw Open. 2022 12 01; 5(12):e2246548. View Abstract
  34. Trends in Dispensing of Controlled Medications for US Adolescents and Young Adults, 2008 to 2019. JAMA Pediatr. 2022 12 01; 176(12):1265-1266. View Abstract
  35. Anatomical barriers against SARS-CoV-2 neuroinvasion at vulnerable interfaces visualized in deceased COVID-19 patients. Neuron. 2022 12 07; 110(23):3919-3935.e6. View Abstract
  36. Regulatory considerations to keep pace with innovation in digital health products. NPJ Digit Med. 2022 Aug 19; 5(1):121. View Abstract
  37. US Food and Drug Administration Approval of High-risk Cardiovascular Devices for Use in Children and Adolescents, 1977-2021. JAMA. 2022 08 09; 328(6):580-582. View Abstract
  38. New legislation to promote paediatric studies for new cancer medicines. Lancet Oncol. 2022 08; 23(8):e368-e369. View Abstract
  39. International electronic health record-derived post-acute sequelae profiles of COVID-19 patients. NPJ Digit Med. 2022 Jun 29; 5(1):81. View Abstract
  40. Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2. BMJ Open. 2022 06 23; 12(6):e057725. View Abstract
  41. Association Between Molecular Streptococcal Testing and Antibiotic Use for Pharyngitis in Children. J Pediatric Infect Dis Soc. 2022 06 22; 11(6):303-304. View Abstract
  42. International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality. NPJ Digit Med. 2022 Jun 13; 5(1):74. View Abstract
  43. A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020. J Pediatric Infect Dis Soc. 2022 May 30; 11(5):191-198. View Abstract
  44. Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis. Clin Trials. 2022 08; 19(4):442-451. View Abstract
  45. Data-Driven Approaches to Maximize the Impact of Pediatric Clinical Trials. Pediatrics. 2022 04 01; 149(4). View Abstract
  46. Trends in Benzodiazepine Prescribing for US Adolescents and Young Adults From 2008 to 2019. JAMA Pediatr. 2022 03 01; 176(3):312-313. View Abstract
  47. National Institutes of Health Funding Priorities-Reply. JAMA Pediatr. 2022 03 01; 176(3):325. View Abstract
  48. Improving FDA postmarket adverse event reporting for medical devices. BMJ Evid Based Med. 2023 04; 28(2):83-84. View Abstract
  49. Identifying unreported links between ClinicalTrials.gov trial registrations and their published results. Res Synth Methods. 2022 May; 13(3):342-352. View Abstract
  50. National assessment of anti-epileptic drug exposures among pre-teens and adolescents, 2000-2020. Clin Toxicol (Phila). 2022 06; 60(6):681-687. View Abstract
  51. Factors Associated With Corticosteroid Treatment for Pediatric Acute Respiratory Tract Infections. J Pediatric Infect Dis Soc. 2021 Dec 31; 10(12):1101-1104. View Abstract
  52. The automation of relevant trial registration screening for systematic review updates: an evaluation study on a large dataset of ClinicalTrials.gov registrations. BMC Med Res Methodol. 2021 12 18; 21(1):281. View Abstract
  53. Correlation Between National Institutes of Health Funding for Pediatric Research and Pediatric Disease Burden in the US. JAMA Pediatr. 2021 12 01; 175(12):1236-1243. View Abstract
  54. Quantifying the feasibility of shortening clinical trial duration using surrogate markers. Stat Med. 2021 12 10; 40(28):6321-6343. View Abstract
  55. Master Protocols and Adaptive Trial Designs to Develop Tumor-Agnostic Drugs for Children: Essential Tools in the Era of the Research to Accelerate Cures and Equity Act. JAMA Oncol. 2021 09 01; 7(9):1281-1282. View Abstract
  56. Assessing the filtration efficiency and regulatory status of N95s and nontraditional filtering face-piece respirators available during the COVID-19 pandemic. BMC Infect Dis. 2021 Jul 29; 21(1):712. View Abstract
  57. Trends in Gabapentin and Pregabalin Prescribing in a Tertiary Pediatric Medical Center. Hosp Pediatr. 2021 08; 11(8):909-914. View Abstract
  58. National Trends in Disease Activity for COVID-19 Among Children in the US. Front Pediatr. 2021; 9:700656. View Abstract
  59. Variation in Intravenous Acetaminophen Use in Pediatric Hospitals: Priorities for Standardization. Hosp Pediatr. 2021 07; 11(7):734-742. View Abstract
  60. International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries. JAMA Netw Open. 2021 06 01; 4(6):e2112596. View Abstract
  61. Development and Validation of a Pediatric Comorbidity Index. Am J Epidemiol. 2021 05 04; 190(5):918-927. View Abstract
  62. Evaluation of Publication of Pediatric Drug Trials. JAMA Netw Open. 2021 04 01; 4(4):e215829. View Abstract
  63. International Comparisons of Harmonized Laboratory Value Trajectories to Predict Severe COVID-19: Leveraging the 4CE Collaborative Across 342 Hospitals and 6 Countries: A Retrospective Cohort Study. medRxiv. 2021 Feb 05. View Abstract
  64. Analysis of SteraMist ionized hydrogen peroxide technology in the sterilization of N95 respirators and other PPE. Sci Rep. 2021 01 21; 11(1):2051. View Abstract
  65. Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents. JAMA Psychiatry. 2021 01 01; 78(1):91-100. View Abstract
  66. Antidiabetic medication use in commercially insured children and adolescents in the United States from 2004 to 2019. Diabetes Obes Metab. 2021 02; 23(2):444-454. View Abstract
  67. The urgent need for research coordination to advance knowledge on COVID-19 in children. Pediatr Res. 2021 08; 90(2):250-252. View Abstract
  68. Incompletely Reported Important Methodological Details and Inaccurate Description of the Formulation That the Control Arms Received in a Gardasil Vaccine Trial. mSphere. 2020 11 04; 5(6). View Abstract
  69. Dynamic Dossier in the Cloud: A Sociotechnical Architecture for a Real-Time and Metrics-Based Data Tracking System with Gene and Cell Therapies as a Case Study. Ther Innov Regul Sci. 2021 03; 55(2):388-400. View Abstract
  70. Pediatric Drug Policies Supporting Safe And Effective Use Of Therapeutics In Children: A Systematic Analysis. Health Aff (Millwood). 2020 10; 39(10):1799-1805. View Abstract
  71. Association of State-Level Opioid-Reduction Policies With Pediatric Opioid Poisoning. JAMA Pediatr. 2020 10 01; 174(10):961-968. View Abstract
  72. Landscape of phase 1 clinical trials for minors with cancer in the United States. Pediatr Blood Cancer. 2020 11; 67(11):e28694. View Abstract
  73. Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19). JAMA Pediatr. 2020 Sep 01; 174(9):825-826. View Abstract
  74. Assessing the quality of nontraditional N95 filtering face-piece respirators available during the COVID-19 pandemic. medRxiv. 2020 Jul 27. View Abstract
  75. Personal Protective Equipment for COVID-19: Distributed Fabrication and Additive Manufacturing. Am J Public Health. 2020 08; 110(8):1162-1164. View Abstract
  76. Is it time for computable evidence synthesis? J Am Med Inform Assoc. 2020 06 01; 27(6):972-975. View Abstract
  77. Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials. JAMA. 2020 May 19; 323(19):1903-1904. View Abstract
  78. Sponsorship of oncology clinical trials in the United States according to age of eligibility. Cancer Med. 2020 07; 9(13):4495-4500. View Abstract
  79. Analysis of SteraMist ionized hydrogen peroxide technology in the sterilization of N95 respirators and other PPE: a quality improvement study. medRxiv. 2020 Apr 23. View Abstract
  80. Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. BMJ Evid Based Med. 2020 Dec; 25(6):213-219. View Abstract
  81. Improving Pediatric Academic Global Health Collaborative Research and Agenda Setting: A Mixed-Methods Study. Am J Trop Med Hyg. 2020 03; 102(3):649-657. View Abstract
  82. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. J Natl Cancer Inst. 2020 03 01; 112(3):224-228. View Abstract
  83. Off-label use of prescription analgesics among hospitalized children in the United States. Pharmacoepidemiol Drug Saf. 2020 04; 29(4):474-481. View Abstract
  84. Correction: The Genomics Research and Innovation Network: creating an interoperable, federated, genomics learning system. Genet Med. 2020 Feb; 22(2):449. View Abstract
  85. The use of opioids in low acuity pediatric trauma patients. PLoS One. 2019; 14(12):e0226433. View Abstract
  86. Developing a pediatric pain data repository. JAMIA Open. 2020 Apr; 3(1):31-36. View Abstract
  87. Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis. PLoS Med. 2019 11; 16(11):e1002966. View Abstract
  88. Prescription opioid use and misuse among adolescents and young adults in the United States: A national survey study. PLoS Med. 2019 11; 16(11):e1002922. View Abstract
  89. The Genomics Research and Innovation Network: creating an interoperable, federated, genomics learning system. Genet Med. 2020 02; 22(2):371-380. View Abstract
  90. Promoting Pediatric Drug Research and Labeling - Outcomes of Legislation. N Engl J Med. 2019 08 29; 381(9):875-881. View Abstract
  91. Importance of authorship and inappropriate authorship assignment in paediatric research in low- and middle-income countries. Trop Med Int Health. 2019 10; 24(10):1229-1242. View Abstract
  92. Trends in Opioid Prescribing for Adolescents and Young Adults in Ambulatory Care Settings. Pediatrics. 2019 06; 143(6). View Abstract
  93. Cost Implications of Escalating Intravenous Acetaminophen Use in Children. JAMA Pediatr. 2019 05 01; 173(5):489-491. View Abstract
  94. Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases. Health Aff (Millwood). 2019 02; 38(2):313-319. View Abstract
  95. The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics. J Clin Epidemiol. 2019 05; 109:62-69. View Abstract
  96. Neglected tropical diseases in children: An assessment of gaps in research prioritization. PLoS Negl Trop Dis. 2019 01; 13(1):e0007111. View Abstract
  97. Trial2rev: Combining machine learning and crowd-sourcing to create a shared space for updating systematic reviews. JAMIA Open. 2019 Apr; 2(1):15-22. View Abstract
  98. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act. JAMA Pediatr. 2019 01 01; 173(1):68-74. View Abstract
  99. Registration of published randomized trials: a systematic review and meta-analysis. BMC Med. 2018 10 16; 16(1):173. View Abstract
  100. Availability of paediatric information in European Medicines Agency approvals. Lancet Child Adolesc Health. 2018 05; 2(5):e9. View Abstract
  101. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study. PLoS Med. 2018 03; 15(3):e1002520. View Abstract
  102. A shared latent space matrix factorisation method for recommending new trial evidence for systematic review updates. J Biomed Inform. 2018 03; 79:32-40. View Abstract
  103. Prevalence of Disclosed Conflicts of Interest in Biomedical Research and Associations With Journal Impact Factors and Altmetric Scores. JAMA. 2018 01 23; 319(4):408-409. View Abstract
  104. Improving the Study of New Medicines for Children With Rare Diseases. JAMA Pediatr. 2018 Jan 01; 172(1):7-9. View Abstract
  105. Unreported links between trial registrations and published articles were identified using document similarity measures in a cross-sectional analysis of ClinicalTrials.gov. J Clin Epidemiol. 2018 03; 95:94-101. View Abstract
  106. Development of the Precision Link Biobank at Boston Children's Hospital: Challenges and Opportunities. J Pers Med. 2017 Dec 15; 7(4). View Abstract
  107. Variation in Pediatric Procedural Sedations Across Children's Hospital Emergency Departments. Hosp Pediatr. 2018 01; 8(1):36-43. View Abstract
  108. The Evolution of Patient Diagnosis: From Art to Digital Data-Driven Science. JAMA. 2017 Nov 21; 318(19):1859-1860. View Abstract
  109. Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis. Pharmacoepidemiol Drug Saf. 2018 02; 27(2):161-167. View Abstract
  110. Variation in the evaluation of testicular conditions across United States pediatric emergency departments. Am J Emerg Med. 2018 Feb; 36(2):208-212. View Abstract
  111. A systematic review of the processes used to link clinical trial registrations to their published results. Syst Rev. 2017 07 03; 6(1):123. View Abstract
  112. Conclusions in systematic reviews of mammography for breast cancer screening and associations with review design and author characteristics. Syst Rev. 2017 05 22; 6(1):105. View Abstract
  113. Complexity and Severity of Pediatric Patients Treated at United States Emergency Departments. J Pediatr. 2017 07; 186:145-149.e1. View Abstract
  114. Exclusion of Elderly People from Randomized Clinical Trials of Drugs for Ischemic Heart Disease. J Am Geriatr Soc. 2017 Nov; 65(11):2354-2361. View Abstract
  115. The Pediatric Research Equity Act Moves Into Adolescence. JAMA. 2017 01 17; 317(3):259-260. View Abstract
  116. Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children. Pediatrics. 2016 09; 138(3). View Abstract
  117. Financial competing interests were associated with favorable conclusions and greater author productivity in nonsystematic reviews of neuraminidase inhibitors. J Clin Epidemiol. 2016 12; 80:43-49. View Abstract
  118. Emergency Department Management of Febrile Respiratory Illness in Children. Pediatr Emerg Care. 2016 Jul; 32(7):429-34. View Abstract
  119. Prevalence and Characteristics of Interventional Trials Conducted Exclusively in Elderly Persons: A Cross-Sectional Analysis of Registered Clinical Trials. PLoS One. 2016; 11(5):e0155948. View Abstract
  120. Conflict of interest disclosure in biomedical research: A review of current practices, biases, and the role of public registries in improving transparency. Res Integr Peer Rev. 2016; 1. View Abstract
  121. Drug-Drug Interactions Among Hospitalized Children Receiving Chronic Antiepileptic Drug Therapy. Hosp Pediatr. 2016 May; 6(5):282-9. View Abstract
  122. Effect of Randomized Clinical Trial Findings on Emergency Management. Acad Emerg Med. 2016 Jan; 23(1):36-47. View Abstract
  123. Measuring patient-perceived quality of care in US hospitals using Twitter. BMJ Qual Saf. 2016 06; 25(6):404-13. View Abstract
  124. Comparison of Drug Utilization Patterns in Observational Data: Antiepileptic Drugs in Pediatric Patients. Paediatr Drugs. 2015 Oct; 17(5):401-10. View Abstract
  125. Variation and Trends in Charges for Pediatric Care in Massachusetts Emergency Departments, 2000-2011. Acad Emerg Med. 2015 Oct; 22(10):1164-71. View Abstract
  126. Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013. Health Res Policy Syst. 2015 Jun 05; 13:28. View Abstract
  127. Identifying Clinical Study Types from PubMed Metadata: The Active (Machine) Learning Approach. Stud Health Technol Inform. 2015; 216:867-71. View Abstract
  128. Citations alone were enough to predict favorable conclusions in reviews of neuraminidase inhibitors. J Clin Epidemiol. 2015 Jan; 68(1):87-93. View Abstract
  129. Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews. Ann Intern Med. 2014 Oct 07; 161(7):513-8. View Abstract
  130. New regulatory paradigms for innovative drugs to treat pediatric diseases. JAMA Pediatr. 2014 Oct; 168(10):879-80. View Abstract
  131. Variation in emergency department admission rates in US children's hospitals. Pediatrics. 2014 Sep; 134(3):539-45. View Abstract
  132. Premarket safety and efficacy studies for ADHD medications in children. PLoS One. 2014; 9(7):e102249. View Abstract
  133. Drug safety in the digital age. N Engl J Med. 2014 Jun 26; 370(26):2460-2. View Abstract
  134. Postmarketing trials and pediatric device approvals. Pediatrics. 2014 May; 133(5):e1197-202. View Abstract
  135. The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children. PLoS One. 2013; 8(12):e84951. View Abstract
  136. Association between pediatric clinical trials and global burden of disease. Pediatrics. 2014 Jan; 133(1):78-87. View Abstract
  137. Adult prescription drug use and pediatric medication exposures and poisonings. Pediatrics. 2013 Jul; 132(1):18-27. View Abstract
  138. Use of QT-prolonging medications in US emergency departments, 1995-2009. Pharmacoepidemiol Drug Saf. 2014 Jan; 23(1):9-17. View Abstract
  139. Analysis of pediatric clinical drug trials for neuropsychiatric conditions. Pediatrics. 2013 Jun; 131(6):1125-31. View Abstract
  140. Industry influence in evidence production. J Epidemiol Community Health. 2013 Jul; 67(7):537-8. View Abstract
  141. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics. 2012 Aug; 130(2):285-92. View Abstract
  142. The role and impact of research agendas on the comparative-effectiveness research among antihyperlipidemics. Clin Pharmacol Ther. 2012 Apr; 91(4):685-91. View Abstract
  143. Comparative effectiveness research: an empirical study of trials registered in ClinicalTrials.gov. PLoS One. 2012; 7(1):e28820. View Abstract
  144. Factors associated with the use of cervical spine computed tomography imaging in pediatric trauma patients. Acad Emerg Med. 2011 Sep; 18(9):905-11. View Abstract
  145. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010 Sep; 19(9):901-10. View Abstract
  146. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med. 2010 Aug 03; 153(3):158-66. View Abstract
  147. Neuroimaging for pediatric head trauma: do patient and hospital characteristics influence who gets imaged? Acad Emerg Med. 2010 Jul; 17(7):694-700. View Abstract
  148. Relative impact of influenza and respiratory syncytial virus in young children. Pediatrics. 2009 Dec; 124(6):e1072-80. View Abstract
  149. Pediatric adverse drug events in the outpatient setting: an 11-year national analysis. Pediatrics. 2009 Oct; 124(4):e744-50. View Abstract
  150. "Left without being seen": a national profile of children who leave the emergency department before evaluation. Ann Emerg Med. 2008 Dec; 52(6):599-605. View Abstract
  151. Evaluation of influenza prevention in the workplace using a personally controlled health record: randomized controlled trial. J Med Internet Res. 2008 Mar 14; 10(1):e5. View Abstract
  152. The value of patient self-report for disease surveillance. J Am Med Inform Assoc. 2007 Nov-Dec; 14(6):765-71. View Abstract
  153. Emergency care for children in pediatric and general emergency departments. Pediatr Emerg Care. 2007 Feb; 23(2):94-102. View Abstract
  154. Influenza and other respiratory virus-related emergency department visits among young children. Pediatrics. 2006 Jul; 118(1):e1-8. View Abstract
  155. Lumbar puncture ordering and results in the pediatric population: a promising data source for surveillance systems. Acad Emerg Med. 2006 Jul; 13(7):767-73. View Abstract
  156. Validation of syndromic surveillance for respiratory infections. Ann Emerg Med. 2006 Mar; 47(3):265.e1. View Abstract
  157. Association of race/ethnicity with emergency department wait times. Pediatrics. 2005 Mar; 115(3):e310-5. View Abstract
  158. Adult patient visits to children's hospital emergency departments. Pediatrics. 2003 Jun; 111(6 Pt 1):1268-72. View Abstract
  159. Retropharyngeal cellulitis in a 5-week-old infant. Pediatrics. 2002 Mar; 109(3):E51. View Abstract

Contact Florence Bourgeois

Print Profile